Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Huang, Clifton
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Recruiting	3	90	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Crohn's Disease	07/27	10/27
SHINE-ON, NCT04844606 / 2020-005311-49: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease	Recruiting	3	150	Europe, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease	07/30	07/30
Karam, Lina Boujaoude
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease	Recruiting	3	90	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company, Eli Lilly and Company	Crohn's Disease	07/27	10/27